九安医疗公告，2025年上半年营业收入7.65亿元，同比下降43.35%。净利润9.2亿元，同比增长 52.91%。 ...

Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed A+ round financing of several tens of millions, led by Jiuan Medical, to accelerate commercialization and continue independent R&D [1][2] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography, which is the leading product in chemical analysis and life sciences [1] - Konomai, established in 2019, focuses on the independent R&D and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [1][2] Company Developments - Konomai has completed a full series layout of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [1] - The company has initiated the construction of a production base in Suzhou since 2022, achieving a domestic component localization rate of 95% [2] - Konomai's sales revenue has been growing at over 50% annually since the start of its commercialization layout in 2023, with overseas market growth exceeding 80% [2] Investment Perspective - Jiuan Medical aims to discover and collaborate with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on deepening independent R&D and leveraging the "Stanford model" [3] - The company emphasizes the importance of the domestic scientific instrument localization trend and policy support to promote import substitution in the global market [3] - Konomai's breakthroughs in the UHPLC field are breaking the long-standing reliance on imports in China's high-end market [3]

证券代码：002432 证券简称：九安医疗 公告编号：2025-056 天津九安医疗电子股份有限公司 主承销商 天津银行股份有限公司 渤海银行股份有限公司、上海浦东发展银行股份有限公司、兴业银行股份有 限公司、中国光大银行股份有限公司、中国银行股份有限公司、中国建设银 号），交易商协会决定接受公司科技创新债券（中期票据）注册，注册金额为35 亿元，注册额度自该《接受注册通知书》落款之日起2年内有效，公司在注册有效 期内可分期发行。具体内容详见公司于2025年8月9日在《证券时报》及巨潮资讯 网（http://www.cninfo.com.cn）披露的《关于中期票据和超短期融资券获准注册的 公告》（公告编号：2025-054）。 公司于2025年8月21日在全国银行间市场簿记并发行了债券简称为"25九安医 疗MTN001(科创债)"的科技创新债券，发行结果如下： 天津九安医疗电子股份 债券名称 有限公司2025年度第一 债券简称 (科创债) | 期科技创新债券 | | | | | --- | --- | --- | --- | | 债券代码 | 102583585 期限 | | 1+1+1年 | | 起息日 | ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-056 天津九安医疗电子股份有限公司 关于2025年度第一期科技创新债券发行结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年6月3日召开 第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关于 拟注册和发行中期票据及超短期融资券的议案》。同意公司向中国银行间市场交 易商协会（以下简称"交易商协会"）申请注册发行总额不超过人民币35亿元（含 35亿元）的中期票据事项。具体内容详见公司于2025年6月5日在《证券时报》及 巨潮资讯网（http://www.cninfo.com.cn）披露的《关于拟注册和发行中期票据及超 短期融资券的公告》（公告编号：2025-049）。 | 发行利率(%) | 1.83 | 发行价(百元面值) | 100.00 | | --- | --- | --- | --- | | 簿记管理人 | 天津银行股份有限公司 | | | | 主承销商 | 天津银行股份有限公司 | | | | 联席 ...

为充分尊重投资者、提升交流质量，现就公司 2025 年半年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 8 月 27 日（星期三）12:00 前将所需了解的情况和问题一并发送至邮箱 ir@jiuan.com。 欢迎广大投资者积极参与，衷心感谢广大投资者对公司发展的关心与支持！ 特此公告。 天津九安医疗电子股份有限公司董事会 关于举办2025年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）2025 年半年度报告将 于 2025 年 8 月 27 日披露于巨潮资讯网（www.cninfo.com.cn），为了让广大投资 者能进一步了解公司 2025 年半年度的经营和财务情况，公司将于 2025 年 8 月 27 日下午 15:00-16:00 在东方财富路演平台举行 2025 年半年度网上业绩说明会。 投资者可登陆东方财富路演平台（http://roadshow.eastmoney.com/luyan/4858672） 进行参与，本次业 ...

Core Viewpoint - The stock price of Jiuan Medical reached 41.60 yuan as of August 21, 2025, reflecting a 0.70% increase from the previous trading day, indicating positive market sentiment towards the company [1]. Group 1: Company Performance - Jiuan Medical's main business includes medical devices and health monitoring equipment, with a focus on diabetes care and health management services [1]. - The revenue from diabetes care business for the full year of 2024 was reported at 76.16 million yuan, with further updates expected in the semi-annual report for the first half of 2025 [1]. - The company aims to continuously optimize its business layout and enhance asset allocation returns to increase long-term value [1]. Group 2: Market Activity - On August 21, 2025, the net inflow of main funds was 11.60 million yuan, while there was a net outflow of 12.86 million yuan over the past five days, indicating fluctuating investor interest [2].

证券日报网讯九安医疗（002432）8月21日在互动平台回答投资者提问时表示，截至2025年8月10日，公 司股东人数约7.3万户。 ...

（文章来源：证券日报） 证券日报网讯九安医疗8月21日在互动平台回答投资者提问时表示，二级市场股价的影响因素较多，短 期波动很难单纯的归因为公司基本面，投资者的认知差异和策略偏好也有不同，导致市场对公司价值的 理解也存在差异，但是，公司相信，从长期的视角来看，公司的基本面会反映出公司的价值，公司将持 续在业务层面发力，不断提升业务及大类资产配置带来的收益，从而提升公司价值。与此同时，公司非 常重视投资者关系，并持续积极地与金融机构及机构投资者保持交流，希望市场可以认同公司的价值， 并给予客观的估值。 ...

Group 1 - The company received an inquiry regarding its diabetes care business revenue for 2025 and its expected growth compared to 2024 [2] - The company reported that the total revenue from its diabetes care business for the year 2024 is projected to reach 76.16 million yuan [2] - The company indicated that details regarding the performance of the diabetes care business in the first half of 2025 will be available in its semi-annual report for that year [2]

Core Viewpoint - The company is actively advancing its "Internet + Healthcare" strategy, particularly focusing on the diabetes O+O model in both the US and China, with significant progress reported in patient management and revenue growth [1] Group 1: Business Development - The diabetes O+O model aims for full implementation in the US and China by the end of 2025, with ongoing expansion efforts [1] - As of the latest report, the model has been established in 50 cities across China and 394 hospitals, managing over 329,000 diabetes patients [1] - In the US, partnerships have been formed with approximately 74 clinics and 388 doctors, serving around 20,000 patients [1] Group 2: Performance Metrics - The management of diabetes patients has shown significant improvement, with the rate of achieving target HbA1c levels increasing from about 30% to 60% [1] - The adverse event rate has decreased to below 5%, and the standardized management rate has improved to 70% [1] - The company reported a revenue of 76.16 million yuan from diabetes care services in 2024 [1]